PRESS-RELEASE filed May 11, 2026 at 06:25 ET
Certara reported Q1 2026 adjusted diluted EPS of $0.09, missing the $0.11 consensus by 15.1%, while revenue of $106.9M was slightly above the $106.1M estimate. The company swung to a GAAP net loss of $8.8M from a $4.7M profit a year ago, driven by higher operating expenses and a $7.4M contingent consideration charge. Guidance for full-year 2026 was updated to reflect the divestiture of the Regulatory and Medical Writing business, with revenue growth of 0%-4% excluding the divested unit and adjusted EPS of $0.35-$0.41.